Quest Diagnostics (DGX) Stock Movement Summary Quest Diagnostics stock gained 6% to $203.18 following the release of fourth quarter and full year 2025 financial results that exceeded expectations. Key Financial Results: - Q4 2025 revenues: $2.81 billion, up 7.1% year-over-year - Q4 diluted EPS: $2.18, up 11.8%; adjusted EPS: $2.42, up 8.5% - Full year 2025 revenues: $11.04 billion, up 11.8% - Full year diluted EPS: $8.75, up 13.8%; adjusted EPS: $9.85, up 10.3% Forward Guidance: - FY2026 revenues expected between $11.70-$11.82 billion - FY2026 GAAP EPS guidance: $9.45-$9.65 Capital Allocation: - Quarterly dividend increased 7.5% to $0.86 per share (15th consecutive year
Read full analysisQuest Diagnostics (DGX) Stock Movement Summary Quest Diagnostics stock gained 6% to $203.18 following the release of fourth quarter and full year 2025 financial results that exceeded expectations. Key Financial Results: - Q4 2025 revenues: $2.81 billion, up 7.1% year-over-year - Q4 diluted EPS: $2.18, up 11.8%; adjusted EPS: $2.42, up 8.5% - Full year 2025 revenues: $11.04 billion, up 11.8% - Full year diluted EPS: $8.75, up 13.8%; adjusted EPS: $9.85, up 10.3% Forward Guidance: - FY2026 revenues expected between $11.70-$11.82 billion - FY2026 GAAP EPS guidance: $9.45-$9.65 Capital Allocation: - Quarterly dividend increased 7.5% to $0.86 per share (15th consecutive year
Quest Diagnostics Inc. (DGX) is a publicly traded company in the Healthcare sector.